# 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

> **NCT00360243** · PHASE3 · COMPLETED · sponsor: **Sprout Pharmaceuticals, Inc** · enrollment: 1385 (actual)

## Conditions studied

- Sexual Dysfunctions, Psychological

## Interventions

- **DRUG:** flibanserin
- **DRUG:** flibanserin
- **DRUG:** flibanserin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00360243
- **Lead sponsor:** Sprout Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 1385 (ACTUAL)
- **Last updated:** 2016-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00360243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00360243, "6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00360243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*